GlaxoSmithKline Pharmaceuticals is a subsidiary of the GSK Group in India. Its objective is to get ahead of disease with the ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2916. The stock has experienced fluctuations ...

GSK Pharma Q3 results 2025: GlaxoSmithKline Pharma Ltd announced its Q3 results today posting a solid jump in its net profit. Consolidated PAT for the quarter surged by a robust 402 per cent.

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a global healthcare company dedicated to leveraging science, technology, and talent to address disease challenges worldwide.

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of ...

Glaxosmithkline Pharmaceuticals Ltd, Marico Ltd, Caplin Point Laboratories Ltd and Aarti Pharmalabs Ltd are among the other losers in the BSE's 'A' group today, 21 April 2025.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ADR stocks ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...